Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, recently launched its “Desire Project” to address and treat female hypoactive sexual desire disorder (“HSDD”) with MDMA-assisted psychotherapy. A first-of-its-kind study, the Desire Project, is targeting HSDD, a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. The study comprises some of the world’s leading researchers in female sexual desire and psychedelics. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from the disorder, which can damage the lives of those it affects, causing depression and anxiety — potentially destroying personal relationships. Men can also suffer from HSDD. A recent article quotes company president and CEO Kelsey Ramsden as saying, “MINDCURE has identified a gap in the market, and I think that with the team we have built to execute this project, we can help those seeking improved desire in a new way.”
To view the full article, visit https://ibn.fm/KkBEQ
About Mind Cure Health Inc.
MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based, psychedelic-assisted therapies globally. For more information about the company, please visit www.MindCure.com.
NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care solutions, announced a commercial agreement with…
NRx Pharmaceuticals (NASDAQ: NRXP) announced that the U.S. Food and Drug Administration cleared the company to…
Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its positioning as cardiovascular…
Oncotelic Therapeutics (OTCQB: OTLC) announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc., granting…
VolitionRx Limited (NYSE American: VNRX) announced submission for peer review of a clinical manuscript demonstrating the high accuracy…
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free…